How many drugs treat Hereditary angioneurotic edema?

Drug Landscape tracks 6 marketed treatments for Hereditary angioneurotic edema (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hereditary-angioneurotic-edema.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hereditary angioneurotic edema — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hereditary angioneurotic edema (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hereditary angioneurotic edema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Orladeyo	BEROTRALSTAT	Biocryst	Plasma Kallikrein Inhibitor	Plasma kallikrein	2020-01-01
Takhzyro	LANADELUMAB	Dyax Corp	Plasma Kallikrein Inhibitor [EPC]	plasma kallikrein	2018-01-01
Firazyr	ICATIBANT	Takeda	Bradykinin B2 Receptor Antagonist	B2 bradykinin receptor	2011-01-01
Kalbitor	ECALLANTIDE	Dyax Corp.	Plasma Kallikrein Inhibitor [EPC]	Plasma kallikrein	2009-01-01
Firazyr	Firazyr	Sebastian Videla		B1 bradykinin receptor, B2 bradykinin receptor, B1 bradykinin receptor
TAKHZYRO	LANADELUMAB-FLYO	DYAX CORP.	Plasma Kallikrein Inhibitor [EPC]	Plasma kallikrein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Hereditary angioneurotic edema
Biocryst · 1 drug in Hereditary angioneurotic edema
DYAX CORP. · 1 drug in Hereditary angioneurotic edema
Dyax Corp · 1 drug in Hereditary angioneurotic edema
Dyax Corp. · 1 drug in Hereditary angioneurotic edema
Sebastian Videla · 1 drug in Hereditary angioneurotic edema
Takeda · 1 drug in Hereditary angioneurotic edema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hereditary angioneurotic edema:

Cite this brief

Drug Landscape (2026). Hereditary angioneurotic edema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hereditary-angioneurotic-edema. Accessed 2026-06-10.

Hereditary angioneurotic edema full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing